Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307133 | 0.73 | CSNK2A1 (0.44) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL824416 | 0.70 | CSNK2A1 (0.55) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL31135882 | 0.70 | CSNK2A1 (0.45) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL20399971 | 0.70 | CSNK2A1 (0.45) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL6307456 | 0.70 | CSNK2A1 (0.41) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL11324919 | 0.70 | CSNK2A1 (0.55) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL20200208 | 0.70 | CSNK2A1 (0.41) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL16475165 | 0.70 | CSNK2A1 (0.45) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL11362326 | 0.68 | CSNK2A1 (0.54) | CSNK2A1DYRK1ACSNK2A2MEN1RAB9A | |
| SCHEMBL5479715 | 0.68 | DPP4 (0.50) | CSNK2A1DPP4ALDH1A1PDPK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1113390-A | — | — | None | — | — | JP | disclosed |
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | SANOFI (FR) | 2026-03-24 | — | — | US | disclosed |
| EP-4288438-B1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025031923-A1 | IMIDAZO[4,5-D]PYRIDAZINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS | SANOFI (FR) | 2025-02-13 | — | — | WO | disclosed |
| US-20240158401-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-05-16 | — | — | US | disclosed |
| EP-4288438-A1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi (FR) | 2023-12-13 | — | — | EP | disclosed |
| CN-117098761-A | Imidazo [4,5-d ] pyridazine derivatives, preparation thereof and therapeutic use thereof | 赛诺菲 | 2023-11-21 | — | — | CN | disclosed |
| WO-2022167438-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-08-11 | — | — | WO | disclosed |
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-20050075309-A1 | Treatment of pestivirus, flavivirus and hepatitis C virus infection by administering tan effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine;viricides; nontoxic; side effects reduction | IDENIX PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| EP-1418179-A2 | Compositions and methods for detecting and modulating rna activity and gene expression | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6262241-B1 | ANTISENSE COMPOUNDS WHICH CLEAVE PHOSPHORODIESTER BONDS AND IMPROVE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF OLIGONUCLEOTIDES, USEFUL IN DIAGNOSING DISEASES | ISIS PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| EP-0604409-A4 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION. | ISIS PHARMACEUTICALS INC (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0604409-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| JP-H01113390-A | 4-HYDRAZINOIMIDAZO(4,5-D)PYRIDAZINE DERIVATIVE AND PRODUCTION THEREOF AND HYPOTENSOR CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | ARAKAWACHIYOUTAROU KK | 1989-05-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | TLR7, TLR8, TLR6 | CSNK2A1 269/4885DYRK1A 3451/4885CSNK2A2 363/4885 |
| US-20050075309-A1 | Treatment of pestivirus, flavivirus and hepatitis C virus infection by administering tan effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine;viricides; nontoxic; side effects reduction | PNP, TPMT, HAVCR2 | CSNK2A1 3725/4885DYRK1A 4258/4885CSNK2A2 3515/4885 |
| US-20240158401-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | TLR7, TLR8, TLR6 | CSNK2A1 1216/4885DYRK1A 1576/4885CSNK2A2 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.